NEW YORK (Reuters Health) - “Major progress” has been achieved in developing chemotherapy combinations to prolong life in patients with ovarian cancer, according to a team of researchers in Greece, the UK, and the US. The top contender appears to be a combination of two types of cancer drugs -- platinums and taxanes -- administered intraperitoneally (directly into the abdominal cavity).>>> Discuss This Story
